Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management
Part of paid clinical trials in Colton, California.
- Sponsor
- Arrowhead Regional Medical Center
- Study ID
- NCT01736449
- Phase
- PHASE4
- Status
- Completed
Conditions
- Pterygium
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — DRUG
Study Details
A pterygium is a fibrovascular growth originating from the conjunctiva that grows onto the surface of the cornea. Frequently, these pterygia will recur even after surgical resection. Bevacizumab is an inhibitor of angiogenesis, which is needed for recurrent growth. The use of bevacizumab is poorly understood in inhibiting pterygium growth. The objective of this study is to compare the effects of wound healing and recurrence rates in postoperative bevacizumab versus pterygium excision alone.
Key Dates
- First listed
- Nov 29, 2012
- Start date
- Apr 30, 2011
- Status verified
- Nov 2012
- Primary completion
- Apr 30, 2012
- Completion
- Apr 30, 2012
Study Design
- Enrollment
- 31 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: Pterygium Excision Alone
- Experimental: Pterygium Excision with Bevacizumab Injection
Primary Outcome Measure
number of recurrent pterygia with postoperative bevacizumab [ Time Frame: 6 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Arrowhead Regional Medical Center | Colton | California | 92624 | - |
Find similar trials in Colton, CA
By research site